Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on MiniMed's Nasdaq Debut Amid Market Volatility

Reuters covered the Nasdaq debut of Medtronic's diabetes business, MiniMed. The company's shares opened 4.8% below their $20 offer price, resulting in a $5.35 billion valuation after raising $560 million. The piece highlights that the new listings market is currently navigating significant challenges, including heightened volatility driven by concerns over AI disruption and geopolitical uncertainties in the Middle East, which have dampened overall investor appetite.

IPOX® Research Associate Lukas Muehlbauer was featured in the article, providing expert commentary on the broader implications of MiniMed's public offering. He weighed in on what the company's decision to list amid high market anxiety signals for the current financial landscape, noting that the company going ahead "shows that the U.S. IPO market is still open, but that it has become a price-sensitive buyers' market".

Read the full article by Arasu Kannagi Basil on Reuters: Medtronic's MiniMed falls in Nasdaq debut, fetches $5.35 billion in valuation